Acuity Technologies Ltd is taking a multi-pronged integrative approach to make a step change to existing strategies. We aspire to deliver safe and efficacious new therapeutic targets for major diseases. Our goal is to enable substantial cost and time savings - potentially saving billions in downstream clinical failures resulting from poor target identification.

 

Acuity is bringing to the fore the mechanistic insights needed to realise AI's true potential in discovering and validating therapeutic targets.

 

Acuity’s biology team is led by Professor David Rubinsztein, Professor of Molecular Neurogenetics at the University of Cambridge and a globally recognised authority on autophagy and neurodegeneration. The AI team is led by two pioneers in explainable AI, underpinned by an experienced board and management team with successful exits.